- A raw-material COA confirms selected incoming attributes; it does not establish stability or safety of the finished cosmetic.
- Compare candidate ingredients on active-peptide basis, including any carrier, counter-ion or copper-complex contribution.
- Screen the actual formula and primary pack under intended storage conditions, with predefined acceptance criteria.
- Document who owns supplier evidence, formulation data, product safety assessment and market-specific claims.
What must be known before a peptide enters a cosmetic formula?
Begin with the exact raw material, not a marketing name. Record its ingredient identity, INCI or applicable common name, peptide or active concentration, supplied form, carriers, preservatives, counter-ions or metal complex where relevant, and recommended storage information. Neat lyophilized powder and a dilute premix can have very different cost and formulation implications. Ask for a lot-specific COA and a technical data sheet that describes the actual commercial material rather than a representative family of products.
The European Union's Cosmetics Regulation requires a safety report that describes qualitative and quantitative composition, physical and chemical characteristics, stability, microbiological quality and impurities of raw materials in its applicable market [1]. That does not prescribe one universal peptide test panel. It does show why ingredient identity and concentration must be established before a formulator can assess a finished product.
- Ingredient name and actual chemical or complex identity
- Active concentration and carrier composition
- Lot-specific COA and technical sheet
- Intended market, product type and packaging
How should pH, solubility and matrix compatibility be screened?
Use a staged screening plan with the proposed commercial matrix, not just a clear solution in a laboratory solvent. The qualified formulation team should compare appearance, precipitation or haze, color, pH drift and the relevant analytical marker in the intended base. Include a no-peptide control so changes caused by the base or packaging are not attributed automatically to the peptide. If the raw material is a copper complex, document the identity and color behavior of that exact complex rather than assuming all copper peptides behave alike.
Set observation times, storage conditions and pass criteria before testing. Keep ingredient supplier suggestions separate from validated results in the finished formula. Published reviews describe peptide physicochemical instability pathways, including changes that depend on sequence and environment [2]. They support a risk-based design but do not establish a universal pH window or shelf life for every cosmetic peptide.
Minimal comparison set
Test the proposed formula with and without the peptide, in the intended primary pack, under controlled and foreseeable storage conditions. Record baseline and follow-up appearance, pH and a justified marker of peptide or complex integrity.
- Visual appearance and phase behavior
- pH and relevant analytical marker
- Matrix control and intended packaging
- Prespecified time points and acceptance limits
What evidence is needed for stability and microbiological quality?
Finished-product evidence should cover the actual formula and container closure under foreseeable storage. A material may remain within raw-material specification yet change after contact with fragrance components, surfactants, metals, light, oxygen or packaging. Decide which measurements reveal a meaningful change for this product, then monitor them over time. An initial appearance check or supplier COA cannot establish a finished-product shelf life.
EU Annex I asks for finished-product stability under reasonably foreseeable conditions and microbiological specifications of substances, mixtures and products [1]. The European Commission's guidance for cosmetic safety reports further discusses preservative challenge testing and the qualified safety assessor's role [3]. The test design and acceptance criteria belong to the responsible formulator and safety team. Avoid using a generalized 'stable for two years' claim unless it is supported by the exact commercial formula and pack.
- Define the formula and pack tested
- Track relevant chemical and physical attributes
- Assess microbiological quality and preservation as applicable
- Investigate deviations and document shelf-life rationale
How should supplier, OEM and brand responsibilities be divided?
The ingredient supplier should identify what is supplied and provide agreed lot evidence. The formulator or OEM should record the commercial formula, processing controls, compatibility data and finished-product tests. The brand or responsible person should retain the required product information, safety assessment, labeling and claims substantiation for the destination market. These responsibilities can be shared contractually, but a supplier's raw-material COA does not transfer the finished-product duty by implication.
Before scale-up, agree on a change-control boundary: a new ingredient lot, alternate carrier, different preservative, altered process or new primary pack may justify targeted repeat tests. Keep a versioned specification and link each stability sample to the formula revision and material lots. This gives procurement, R&D and quality teams a common record when a later batch differs from the pilot.
- Supplier: identity, lot COA and change notification
- Formulator/OEM: processing and finished-formula evidence
- Brand/responsible person: safety report, labeling and claims
- All parties: versioned records and escalation path
This article is for laboratory, analytical, procurement and qualified cosmetic-science contexts. It is not medical advice and does not provide dosing, administration or personal-use instructions.
Frequently asked questions
Does a peptide COA prove a serum will remain stable?+
No. It reports selected attributes of the incoming lot. Stability must be assessed in the actual finished formula and primary packaging under a justified test plan.
Can one compatibility result cover every cosmetic peptide?+
No. Sequence, concentration, salt or complex form, carrier and formula matrix can differ. Use results from the exact material or justify a scientifically sound bridge.
Is a listed INCI name proof that an ingredient is approved for every cosmetic use?+
No. An ingredient name supports identification and labeling, while safety, restrictions and claims must be assessed for the destination market and finished product.
Who owns the finished-product safety assessment?+
The responsible person and qualified safety assessor under the applicable jurisdiction. Supplier documents provide inputs but do not replace the finished-product assessment.